| Code | CSB-RA846617MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to brodalumab, targeting human interleukin-17 receptor A (IL17RA). IL17RA is a crucial cell surface receptor that binds multiple IL-17 family cytokines, including IL-17A and IL-17F, mediating pro-inflammatory signaling pathways involved in immune defense and inflammatory responses. Upon ligand binding, IL17RA activates downstream cascades that promote the production of inflammatory mediators, chemokines, and antimicrobial peptides. Dysregulated IL17RA signaling has been implicated in various autoimmune and inflammatory conditions, particularly psoriasis, psoriatic arthritis, and other immune-mediated disorders where IL-17 pathway overactivation drives pathological inflammation.
Brodalumab is a fully humanized IgG2 monoclonal antibody that functions by blocking IL17RA, thereby preventing multiple IL-17 cytokines from binding and initiating inflammatory cascades. This biosimilar antibody serves as a valuable research tool for investigating IL-17-mediated inflammatory mechanisms, studying receptor-ligand interactions, and exploring therapeutic targeting strategies in preclinical models of autoimmune and inflammatory diseases. It enables researchers to examine the role of IL17RA signaling in disease pathogenesis and evaluate potential immunomodulatory approaches.
There are currently no reviews for this product.